Paper39733180
Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study.
Lee YJ and 4 others. Sci Rep, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study. Papers, record 39733180. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39733180
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Proton Pump Inhibitors | Major topic |
| Kidney Failure, Chronic | Major topic |
| Disease Progression | Major topic |
| Humans | |
| Male | |
| Female | |
| Republic of Korea | |
| Aged | |
| Middle Aged | |
| Incidence | |
| Histamine H2 Antagonists | |
| Renal Insufficiency, Chronic | |
| Risk Factors | |
| Proportional Hazards Models | |
| Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 202400620001 | Biomedical Research Institute Grant Pusan National University Hospital | PubMed |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27082596 | Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study. | Medicine (Baltimore) | 2016 | https://conductscience.org/library/papers/27082596 | PubMed |
| 2 | 32970396 | Dapagliflozin in Patients with Chronic Kidney Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32970396 | PubMed |
| 3 | 31251364 | Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis. | QJM | 2019 | https://conductscience.org/library/papers/31251364 | PubMed |
| 4 | 26752337 | Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. | JAMA Intern Med | 2016 | https://conductscience.org/library/papers/26752337 | PubMed |
| 5 | 24927897 | Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. | Am J Kidney Dis | 2014 | https://conductscience.org/library/papers/24927897 | PubMed |
| 6 | 31606235 | Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. | Am J Kidney Dis | 2020 | https://conductscience.org/library/papers/31606235 | PubMed |
| 7 | 27487959 | Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. | BMC Nephrol | 2016 | https://conductscience.org/library/papers/27487959 | PubMed |
| 8 | 37794003 | Scalable Infrastructure Supporting Reproducible Nationwide Healthcare Data Analysis toward FAIR Stewardship. | Sci Data | 2023 | https://conductscience.org/library/papers/37794003 | PubMed |
| 9 | 37420019 | Proton pump inhibitor use: systematic review of global trends and practices. | Eur J Clin Pharmacol | 2023 | https://conductscience.org/library/papers/37420019 | PubMed |
| 10 | 35656154 | Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research. | J Lipid Atheroscler | 2022 | https://conductscience.org/library/papers/35656154 | PubMed |
| 11 | 26389094 | Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. | CMAJ Open | 2015 | https://conductscience.org/library/papers/26389094 | PubMed |
| 12 | 34266395 | Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. | BMC Nephrol | 2021 | https://conductscience.org/library/papers/34266395 | PubMed |
| 13 | 36331190 | Empagliflozin in Patients with Chronic Kidney Disease. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36331190 | PubMed |
| 14 | 32718584 | Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. | Therapie | 2021 | https://conductscience.org/library/papers/32718584 | PubMed |
| 15 | 30419006 | Correction: Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. | PLoS One | 2018 | https://conductscience.org/library/papers/30419006 | PubMed |
| 16 | 28583827 | Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. | Gastroenterology | 2017 | https://conductscience.org/library/papers/28583827 | PubMed |
| 17 | 27080976 | Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. | J Am Soc Nephrol | 2016 | https://conductscience.org/library/papers/27080976 | PubMed |
| 18 | 33368448 | Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study. | Br J Clin Pharmacol | 2021 | https://conductscience.org/library/papers/33368448 | PubMed |
| 19 | 38311359 | Kidney Health Plan 2033 in Korea: bridging the gap between the present and the future. | Kidney Res Clin Pract | 2024 | https://conductscience.org/library/papers/38311359 | PubMed |
| 20 | 38269952 | Health-Analytics Data to Evidence Suite (HADES): Open-Source Software for Observational Research. | Stud Health Technol Inform | 2024 | https://conductscience.org/library/papers/38269952 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41737121 | Proton Pump Inhibitors and Risk of Chronic Kidney Disease: A Systematic Review and Meta-Analysis. | Cureus | 2026 | https://conductscience.org/library/papers/41737121 | PubMed |
| 41300464 | In Vivo Studies on the Interaction Between Orally Administered Nitrite and Omeprazole: Beyond Proton-Catalyzed S-Nitrosation. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/41300464 | PubMed |
| 41109745 | Digital Proton Pump Inhibitor Prescribing Education at The Point of Prescription: A Real-World Study in a Primary Care Setting. | J Prim Care Community Health | 2025 | https://conductscience.org/library/papers/41109745 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39733180
GET https://conductscience.org/api/papers/v1/39733180/authors